It is thus clear that t(4;11)+ pro-B ALL has a lower mutation rate than other subtypes of B cell leukaemia, suggesting that MLL-AF4 alone is sufficient to initiate disease. This evidence concerns the gene KMT2A and acute lymphoblastic leukemia.